Peter Liljestrom
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Journal: Nature communications
Published: February 18, 2021
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.
Journal: Scientific reports
Published: October 07, 2020
A materials-science perspective on tackling COVID-19.
Journal: Nature reviews. Materials
Published: September 14, 2020
Infectious RNA vaccine protects mice against chikungunya virus infection.
Journal: Scientific reports
Published: August 12, 2020
Seroreactivity to Chikungunya and West Nile Viruses in Rwandan Blood Donors.
Journal: Vector borne and zoonotic diseases (Larchmont, N.Y.)
Published: June 28, 2019
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Journal: Journal of virology
Published: January 11, 2019
DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.
Journal: Scientific reports
Published: March 23, 2018
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Journal: Journal of virology
Published: March 02, 2018
Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Journal: JCI insight
Published: March 30, 2017
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Journal: Nature communications
Published: August 02, 2016
Last Updated: 09/26/2026